Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | AR | P10275 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522031 | 1.00 | PGR (0.61) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL18971904 | 1.00 | PGR (0.61) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL12524081 | 1.00 | PGR (0.61) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL14680126 | 0.93 | PGR (0.56) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL2296903 | 0.93 | PGR (0.56) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL12528262 | 0.91 | HIF1A (0.55) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL16523019 | 0.89 | PGR (0.56) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL24622441 | 0.88 | HIF1A (0.61) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL6523590 | 0.88 | HIF1A (0.61) | PGRNR1I2HTR2BHIF1ACYP3A4 | |
| SCHEMBL2300385 | 0.88 | HIF1A (0.61) | PGRNR1I2HTR2BHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475676-B1 | Pregnane derivatives condensed in the 16,17 position with an N-substituted isoxazolidine ring as anti-inflammatory agents | CHIESI FARM SPA (IT) | 2020-05-27 | — | — | EP | disclosed |
| US-10280193-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-10280193-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20180066010-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-08 | — | — | US | disclosed |
| US-20180066010-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-08 | — | — | US | disclosed |
| US-20180066010-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-08 | — | — | US | disclosed |
| US-9845337-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-19 | — | — | US | disclosed |
| US-9845337-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-19 | — | — | US | disclosed |
| US-9845337-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-19 | — | — | US | disclosed |
| EP-2716648-B1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARM SPA (IT) | 2017-06-14 | — | — | EP | disclosed |
| WO-2012123482-A2 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | WO | disclosed |
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | US | disclosed |
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | US | disclosed |
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | US | disclosed |
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| WO-2011095535-A2 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-11 | — | — | WO | disclosed |
| US-20110065678-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-03-17 | — | — | US | disclosed |
| US-20110065678-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | IL5, TSLP, SERPINA6 | PGR 2154/4885NR1I2 139/4885HTR2B 379/4885 |
| US-20110065678-A1 | ISOXAZOLIDINE DERIVATIVES | NR3C2, NR3C1, MC2R | PGR 1856/4885NR1I2 156/4885HTR2B 121/4885 |
| US-20180066010-A1 | ISOXAZOLIDINE DERIVATIVES | IL5, TSLP, SERPINA6 | PGR 2154/4885NR1I2 139/4885HTR2B 379/4885 |
| US-10280193-B2 | Isoxazolidine derivatives | IL5, TSLP, SERPINA6 | PGR 2154/4885NR1I2 139/4885HTR2B 379/4885 |
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | IL5, TSLP, NR3C1 | PGR 215/4885NR1I2 743/4885HTR2B 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.